<?xml version="1.0" encoding="UTF-8"?>
<p>Secondly, studies on the design of antiviral agents based on the structure and function of viral and human receptor proteins in Korea (Sub-Cluster 2-2) were composed of 25 projects worth 11,676,155 USD. Institut Pasteur Korea has pledged to spend 3 million USD on the project entitled “Preparedness of emerging viruses” between 2017 and 2022. Ilyang Pharmaceutical Co., Ltd. and Hallym University also have concentrated on a similar project, “Deriving new candidates for the development of therapeutics in the Middle East Respiratory Syndrome”, with budgeted expenditures of 763,636 and “Development therapeutic target and candidate for immunotherapy against middle east respiratory syndrome coronavirus (MERS-CoV)” with a budget of 418,182 USD between 2016 and 2021, respectively (see 
 <xref rid="healthcare-08-00204-t012" ref-type="table">Table 12</xref>).
</p>
